Dexcom vs ResMed|
Prices at close . Model readings .
Dexcom
$78.62+0.08%- Market value
- $30.67B
- P/E
- 29.0
- 1 year
- +11.3%
ResMed|
$250.17−0.25%- Market value
- $36.54B
- P/E
- 18.7
- 1 year
- −2.5%
Price change, with the S&P 500 as a benchmark
Percent change in each close since the start of the chosen range, for both companies and the S&P 500 (SPY). Daily closes over the last year, weekly before that and monthly before five years.
How the two compare
On the latest closes (28 Oct 2026), ResMed| is the larger company by market value ($36.54B against $30.67B). Over the past year Dexcom returned +11.3% and ResMed| −2.5%, while the S&P 500 returned +12.7%. The latest filed P/E is 29.0 for Dexcom and 18.7 for ResMed|, and the operating margin 24.3% against 33.4%. Over the next 21 sessions the model expects +0.11% for Dexcom, with a 43% chance of a rise, and −0.04% for ResMed|, with a 44% chance. Dexcom's long-run fair value is $68.02, a gap of −13.5% to its price; the long-run model view is negative. ResMed|'s long-run fair value is $205.74, a gap of −17.8% to its price; the long-run model view is negative.
What the model expects
Expected returns and the chance of a rise from our forecasting models, and the long-run fair value against the price. Readings, not advice.
How the prices moved
Price change over each period, with the S&P 500 (SPY) for comparison.
What the market pays
Size and the multiples from the latest filed quarter. A P/E on losses reads n/m.
How much of revenue becomes profit
Margins and returns on capital from the latest filing; revenue, net income and earnings per share over the trailing twelve months.
How fast the business grew
Change against the same quarter a year earlier.
Balance sheet and quality scores
Leverage, liquidity and two published scores: Altman Z (below 1.8 the distress zone, above 3 the safe zone) and Piotroski F (0 to 9).
How the shares trade
Volatility, sensitivity to the market, the deepest fall, short interest and how closely the two move together.
Dexcom or ResMed|: common questions
Which is larger by market value, Dexcom or ResMed|?
ResMed|, at $36.54B against $30.67B for Dexcom, on the latest closes (28 Oct 2026).
Which has the higher P/E ratio, Dexcom or ResMed|?
Dexcom has the higher latest filed P/E, 29.0; ResMed|'s is 18.7. Filings: quarter to 30 Jun 2026.
How did Dexcom and ResMed| move over the past year against the S&P 500?
Over the past year Dexcom returned +11.3% and ResMed| −2.5%, while the S&P 500 returned +12.7%. Prices at close 28 Oct 2026.
What does the model expect for Dexcom and ResMed| over the next month?
+0.11% for Dexcom with a 43% chance of a rise, and −0.04% for ResMed| with a 44% chance, over the next 21 sessions. Model readings 28 Oct 2026. These are model readings, not advice.
How do the operating margins of Dexcom and ResMed| compare?
The operating margin is 24.3% for Dexcom and 33.4% for ResMed|, and the gross margin 63.4% against 61.1%. Filings: quarter to 30 Jun 2026.
Do Dexcom and ResMed| shares move together?
Over the past year the correlation of their daily returns was 0.33 (loosely together); 1 means they always move together, 0 unrelated, −1 opposite. Prices at close 28 Oct 2026.
Model readings are research estimates, not investment advice. Prices: daily closes. Fundamentals: the latest SEC filings. Short interest: FINRA, settlement 30 Sep 2026. A dash means the figure is not in our data; it is never shown as zero. The model view follows a published rule: next month by the sign of the expected return, the long run positive at a fair value 10% or more above the price and negative at 10% or more below it.